Takeda drug impresses in ulcerative colitis study

<p>(Reuters) More than 40 percent of patients with assuage to critical ulcerative colitis achieved clinical discount from a debilitating condition after a year of holding an experimental drug grown by Japans Takeda Pharmaceutical Co, according to information from a pivotal late-stage trial.
The biologic drug, vedolizumab, met a goals of a Phase III hearing with rarely statistically poignant advantages in rates of remission, clinical response and bowel recovering compared with a placebo, researchers said.
Of a patients holding partial in a year-long upkeep study, 44.8 percent of those who perceived vedolizumab each 4 weeks and 41.8 percent who got a drug each 8 weeks were deemed to be in clinical discount during week 52. That compares with 15.9 percent for those who perceived a placebo.
In a subset of patients who were not also holding a steroid for a condition, a discount rate was 45.2 percent for those who got a Takeda drug each 4 weeks...